Oculis Holding AG

NasdaqGM:OCS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🕶 Eyewear

💊 Pharmaceuticals

Location

Switzerland

Market Cap

USD 994.14 M

Share Price

USD 19.48

Avg Daily Volume

36,771

Change (1 day)

-1.27%

Change (1 year)

65.79%

Change (YTD)

14.59%

Oculis Holding AG Price to Sales Ratio (P/S) on June 18, 2025: 3,635.70

Oculis Holding AG Price to Sales Ratio (P/S) is 3,635.70 on June 18, 2025, a 626.03% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Oculis Holding AG 52-week low Price to Sales Ratio (P/S) is 3,717.82 on June 18, 2025, which is 2.26% above the current Price to Sales Ratio (P/S).
Oculis Holding AG 52-week low Price to Sales Ratio (P/S) is 468.98 on June 18, 2025, which is -87.10% below the current Price to Sales Ratio (P/S).
Oculis Holding AG average Price to Sales Ratio (P/S) for the last 52 weeks is 1,534.37.

Daily

From:

To:

Zoom:

Key data

Date	Price to Sales Ratio (P/S)	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield

NasdaqGM: OCS

Oculis Holding AG

CEO	Dr. Riad Sherif M.B.A., M.D.
IPO Date	May 18, 2021
Location	Switzerland
Headquarters	Bahnhofstrasse 7
Employees	49
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🕶 Eyewear 💊 Pharmaceuticals

Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.